T1	Participants 590 623	patients with active RA (n = 507)
T2	Participants 377 532	active rheumatoid arthritis (RA) in patients receiving a stable background regimen of methotrexate (MTX) who have an inadequate response to MTX monotherapy
T3	Participants 1960 2031	patients with active RA in whom the response to MTX has been inadequate
